Combigene Valuation
| COMBI Stock | SEK 2.34 0.06 2.50% |
Based on Macroaxis valuation methodology, the firm appears to be overvalued. Combigene AB shows a prevailing Real Value of kr2.04 per share. The current price of the firm is kr2.34. Our model approximates the value of Combigene AB from analyzing the firm fundamentals such as Current Valuation of 125.36 M, profit margin of 0.59 %, and Return On Equity of 0.48 as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Combigene's price fluctuation is risky at this time. Calculation of the real value of Combigene AB is based on 3 months time horizon. Increasing Combigene's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Combigene stock is determined by what a typical buyer is willing to pay for full or partial control of Combigene AB. Since Combigene is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Combigene Stock. However, Combigene's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.34 | Real 2.04 | Hype 2.4 | Naive 2.39 |
The intrinsic value of Combigene's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Combigene's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Combigene AB helps investors to forecast how Combigene stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Combigene more accurately as focusing exclusively on Combigene's fundamentals will not take into account other important factors: Combigene Total Value Analysis
Combigene AB is currently projected to have takeover price of 125.36 M with market capitalization of 165.53 M, debt of 0, and cash on hands of 34.09 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Combigene fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
125.36 M | 165.53 M | 0 | 34.09 M |
Combigene Investor Information
About 31.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.06. Some equities with similar Price to Book (P/B) outperform the market in the long run. Combigene AB had not issued any dividends in recent years. The entity had 1:20 split on the 7th of June 2021. Based on the measurements of operating efficiency obtained from Combigene's historical financial statements, Combigene AB is not in a good financial situation at the moment. It has a very high risk of going through financial straits in August.Combigene Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Combigene has an asset utilization ratio of 50.56 percent. This implies that the Company is making kr0.51 for each dollar of assets. An increasing asset utilization means that Combigene AB is more efficient with each dollar of assets it utilizes for everyday operations.Combigene Ownership Allocation
Combigene holds a total of 19.8 Million outstanding shares. Combigene AB retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Combigene Profitability Analysis
The company reported the revenue of 84.04 M. Net Income was 20.96 M with profit before overhead, payroll, taxes, and interest of 36.56 M.About Combigene Valuation
The stock valuation mechanism determines Combigene's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Combigene AB based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Combigene. We calculate exposure to Combigene's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Combigene's related companies.CombiGene AB engages in the development and commercialization of gene therapy for the treatment of neurological and psychiatric disorders. CombiGene AB was founded in 1999 and is headquartered in Lund, Sweden. Combigene operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 7 people.
8 Steps to conduct Combigene's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Combigene's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Combigene's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Combigene's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Combigene's revenue streams: Identify Combigene's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Combigene's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Combigene's growth potential: Evaluate Combigene's management, business model, and growth potential.
- Determine Combigene's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Combigene's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Additional Tools for Combigene Stock Analysis
When running Combigene's price analysis, check to measure Combigene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Combigene is operating at the current time. Most of Combigene's value examination focuses on studying past and present price action to predict the probability of Combigene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Combigene's price. Additionally, you may evaluate how the addition of Combigene to your portfolios can decrease your overall portfolio volatility.